Literature DB >> 10850405

Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods.

R Jelliffe1, A Schumitzky, M Van Guilder.   

Abstract

As clinicians acquire experience with the clinical and pharmacokinetic behavior of a drug, it is usually optimal to record this experience in the form of a population pharmacokinetic model, and then to relate the behavior of the model to the clinical effects of the drug or to a linked pharmacodynamic model. The role of population modeling is thus to describe and record clinical experience with the behavior of a drug in a certain group or population of patients or subjects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10850405     DOI: 10.1097/00007691-200006000-00019

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  18 in total

1.  Pharmacokinetic studies in patients on continuous renal replacement therapies.

Authors:  U F Kroh
Journal:  Intensive Care Med       Date:  2001-04       Impact factor: 17.440

Review 2.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate.

Authors:  Markus Joerger; Andrés J M Ferreri; Stephan Krähenbühl; Jan H M Schellens; Thomas Cerny; Emanuele Zucca; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

4.  Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models.

Authors:  Paul G Baverel; Radojka M Savic; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-13       Impact factor: 2.745

5.  Parametric and nonparametric population methods.

Authors:  Johannes H Proost; Douglas J Eleveld
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates.

Authors:  Sandrine Micallef; Billy Amzal; Véronique Bach; Karen Chardon; Pierre Tourneux; Frédéric Y Bois
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Evaluation of the nonparametric estimation method in NONMEM VI: application to real data.

Authors:  Paul G Baverel; Radojka M Savic; Justin J Wilkins; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-07-02       Impact factor: 2.745

9.  Reevaluation of ceftazidime dosing recommendations in patients on continuous ambulatory peritoneal dialysis.

Authors:  Katie E Cardone; Darren W Grabe; Evan J Zasowski; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

10.  Stochastic differential equations in NONMEM: implementation, application, and comparison with ordinary differential equations.

Authors:  Christoffer W Tornøe; Rune V Overgaard; Henrik Agersø; Henrik A Nielsen; Henrik Madsen; E Niclas Jonsson
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.